Skip to main content

Peer Review reports

From: A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer

Original Submission
18 May 2023 Submitted Original manuscript
21 Jun 2023 Reviewed Reviewer Report
23 Aug 2023 Reviewed Reviewer Report - Stefano Natangelo
22 Sep 2023 Author responded Author comments - hanqiao shao
Resubmission - Version 2
22 Sep 2023 Submitted Manuscript version 2
3 Oct 2023 Reviewed Reviewer Report
8 Oct 2023 Reviewed Reviewer Report - Stefano Natangelo
30 Oct 2023 Author responded Author comments - hanqiao shao
Resubmission - Version 3
30 Oct 2023 Submitted Manuscript version 3
6 Nov 2023 Reviewed Reviewer Report - Stefano Natangelo
8 Nov 2023 Reviewed Reviewer Report
22 Nov 2023 Author responded Author comments - hanqiao shao
Resubmission - Version 4
22 Nov 2023 Submitted Manuscript version 4
5 Dec 2023 Reviewed Reviewer Report
18 Dec 2023 Author responded Author comments - hanqiao shao
Resubmission - Version 5
18 Dec 2023 Submitted Manuscript version 5
Publishing
19 Dec 2023 Editorially accepted
12 Jan 2024 Article published 10.1186/s12916-023-03238-2

You can find further information about peer review here.

Back to article page